-
1.
GSK. Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis. February 1, 2023. https://www.gsk.com/en-gb/media/press-releases/jesduvroq-daprodustat-approved-by-us-fda-for-anaemia-of-chronic-kidney-disease-in-adults-on-dialysis/
-
2.
CSL. Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients. March 28, 2024. https://newsroom.csl.com/2024-03-28-Vafseo-R-approved-by-the-U-S-FDA-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-dialysis-dependent-adult-patients
-
3.
Avalere. How the transitional drug add-on payment adjustment works. Updated October 5, 2023. https://avalere.com/insights/how-the-transitional-drug-add-on-payment-adjustment-tdapa-works
-
4.
National Archives and Records Administration. Proposed rules. Federal Register. July 5, 2024; 89(129):55832. https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/FR-2024-07-05.pdf
-
5.
Tolson S. Taking a closer look at TDAPA medication reimbursement. docwirenews. Updated February 5, 2024. https://docwirenews.com/post/taking-a-closer-look-at-tdapa-medication-reimbursement
-
6.
Sonia SN, et al. An overview of safety and efficacy between hypoxia-inducible factor-prolyl-hydroxylase inhibitors and erythropoietin-stimulating agents in treating anemia in chronic kidney disease patients. Cureus 2023; 15:e42045. doi: 10.7759/cureus.42045
Understanding the TDAPA for Treating Anemia in Patients on Dialysis
Search for other papers by Katherine Kwon in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory